-
1
-
-
84863059988
-
-
European Medicines Agency (EMEA). Scientific discussion vildagliptin.
-
European Medicines Agency (EMEA). Scientific discussion vildagliptin. 2007.
-
(2007)
-
-
-
2
-
-
34248223285
-
Biology of incretins: GLP-1 and GIP
-
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-57.
-
(2007)
Gastroenterology
, vol.132
, pp. 2131-2157
-
-
Baggio, L.L.1
Drucker, D.J.2
-
3
-
-
0032871230
-
GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans
-
Naslund E, Bogefors J, Skogar S, Gryback P, Jacobsson H, Holst JJ, Hellstrom PM. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999; 277: R910-6.
-
(1999)
Am J Physiol
, vol.277
-
-
Naslund, E.1
Bogefors, J.2
Skogar, S.3
Gryback, P.4
Jacobsson, H.5
Holst, J.J.6
Hellstrom, P.M.7
-
4
-
-
33846006173
-
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
-
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705.
-
(2006)
Lancet
, vol.368
, pp. 1696-1705
-
-
Drucker, D.J.1
Nauck, M.A.2
-
5
-
-
0027391607
-
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
-
Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-7.
-
(1993)
J Clin Invest
, vol.91
, pp. 301-307
-
-
Nauck, M.A.1
Heimesaat, M.M.2
Orskov, C.3
Holst, J.J.4
Ebert, R.5
Creutzfeldt, W.6
-
6
-
-
34347393269
-
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus
-
He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, Holst JJ, Schwartz S, Nielsen JC, Ligueros-Saylan M. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007; 46: 577-88.
-
(2007)
Clin Pharmacokinet
, vol.46
, pp. 577-588
-
-
He, Y.L.1
Serra, D.2
Wang, Y.3
Campestrini, J.4
Riviere, G.J.5
Deacon, C.F.6
Holst, J.J.7
Schwartz, S.8
Nielsen, J.C.9
Ligueros-Saylan, M.10
-
7
-
-
84863018661
-
Mechanism-based population pharmacokinetic modelling in diabetic patients: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV
-
Landersdorfer CB, He Y-L, Jusko WJ. Mechanism-based population pharmacokinetic modelling in diabetic patients: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. Br J Clin Pharmacol 2012; 73: 391-401.
-
(2012)
Br J Clin Pharmacol
, vol.73
, pp. 391-401
-
-
Landersdorfer, C.B.1
He, Y.-L.2
Jusko, W.J.3
-
8
-
-
84863043397
-
-
S-ADAPT/MCPEM user's guide (version 1.56). Software for Pharmacokinetic, Pharmacodynamic and Population Data Analysis. Berkeley, CA.
-
Bauer RJ. S-ADAPT/MCPEM user's guide (version 1.56). Software for Pharmacokinetic, Pharmacodynamic and Population Data Analysis. Berkeley, CA. 2008.
-
(2008)
-
-
Bauer, R.J.1
-
9
-
-
0035216180
-
Ways to fit a PK model with some data below the quantification limit
-
Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481-504.
-
(2001)
J Pharmacokinet Pharmacodyn
, vol.28
, pp. 481-504
-
-
Beal, S.L.1
-
10
-
-
45549108317
-
Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus
-
Landersdorfer CB, Jusko WJ. Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. Clin Pharmacokinet 2008; 47: 417-48.
-
(2008)
Clin Pharmacokinet
, vol.47
, pp. 417-448
-
-
Landersdorfer, C.B.1
Jusko, W.J.2
-
11
-
-
31544436629
-
Minimal model: perspective from 2005
-
Bergman RN. Minimal model: perspective from 2005. Horm Res 2005; 64: (Suppl. 3): 8-15.
-
(2005)
Horm Res
, vol.64
, Issue.3 SUPPL.
, pp. 8-15
-
-
Bergman, R.N.1
-
12
-
-
3042559890
-
Modeling the metabolic effects of terbutaline in beta2-adrenergic receptor diplotypes
-
Lima JJ, Matsushima N, Kissoon N, Wang J, Sylvester JE, Jusko WJ. Modeling the metabolic effects of terbutaline in beta2-adrenergic receptor diplotypes. Clin Pharmacol Ther 2004; 76: 27-37.
-
(2004)
Clin Pharmacol Ther
, vol.76
, pp. 27-37
-
-
Lima, J.J.1
Matsushima, N.2
Kissoon, N.3
Wang, J.4
Sylvester, J.E.5
Jusko, W.J.6
-
13
-
-
6244309282
-
Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique
-
Mager DE, Abernethy DR, Egan JM, Elahi D. Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique. J Pharmacol Exp Ther 2004; 311: 830-5.
-
(2004)
J Pharmacol Exp Ther
, vol.311
, pp. 830-835
-
-
Mager, D.E.1
Abernethy, D.R.2
Egan, J.M.3
Elahi, D.4
-
14
-
-
0037844361
-
Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative
-
Agerso H, Vicini P. Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. Eur J Pharm Sci 2003; 19: 141-50.
-
(2003)
Eur J Pharm Sci
, vol.19
, pp. 141-150
-
-
Agerso, H.1
Vicini, P.2
-
16
-
-
77649202720
-
An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers
-
Silber HE, Frey N, Karlsson MO. An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers. J Clin Pharmacol 2010; 50: 246-56.
-
(2010)
J Clin Pharmacol
, vol.50
, pp. 246-256
-
-
Silber, H.E.1
Frey, N.2
Karlsson, M.O.3
-
17
-
-
79955754193
-
Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice
-
Chan HM, Jain R, Ahren B, Pacini G, D'Argenio DZ. Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice. Am J Physiol Regul Integr Comp Physiol 2011; 300: R1126-33.
-
(2011)
Am J Physiol Regul Integr Comp Physiol
, vol.300
-
-
Chan, H.M.1
Jain, R.2
Ahren, B.3
Pacini, G.4
D'Argenio, D.Z.5
-
18
-
-
79951962530
-
Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats
-
Gao W, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. J Pharmacol Exp Ther 2011; 336: 881-90.
-
(2011)
J Pharmacol Exp Ther
, vol.336
, pp. 881-890
-
-
Gao, W.1
Jusko, W.J.2
-
19
-
-
24944436267
-
Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig
-
Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 2005; 48: 1882-90.
-
(2005)
Diabetologia
, vol.48
, pp. 1882-1890
-
-
Plamboeck, A.1
Holst, J.J.2
Carr, R.D.3
Deacon, C.F.4
-
20
-
-
0029111540
-
Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides
-
Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Goke R, Goke B, Thole H, Zimmermann B, Voigt K. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 1995; 58: 149-56.
-
(1995)
Regul Pept
, vol.58
, pp. 149-156
-
-
Hupe-Sodmann, K.1
McGregor, G.P.2
Bridenbaugh, R.3
Goke, R.4
Goke, B.5
Thole, H.6
Zimmermann, B.7
Voigt, K.8
-
21
-
-
1442350411
-
Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects
-
Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004; 53: 654-62.
-
(2004)
Diabetes
, vol.53
, pp. 654-662
-
-
Meier, J.J.1
Nauck, M.A.2
Kranz, D.3
Holst, J.J.4
Deacon, C.F.5
Gaeckler, D.6
Schmidt, W.E.7
Gallwitz, B.8
-
22
-
-
0035041250
-
Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats
-
Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 2001; 50: 1004-11.
-
(2001)
Diabetes
, vol.50
, pp. 1004-1011
-
-
Lynn, F.C.1
Pamir, N.2
Ng, E.H.3
McIntosh, C.H.4
Kieffer, T.J.5
Pederson, R.A.6
-
23
-
-
15944404686
-
The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases
-
Augustyns K, Van der Veken P, Senten K, Haemers A. The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. Curr Med Chem 2005; 12: 971-98.
-
(2005)
Curr Med Chem
, vol.12
, pp. 971-998
-
-
Augustyns, K.1
Van der Veken, P.2
Senten, K.3
Haemers, A.4
-
24
-
-
23044517378
-
Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon?
-
Raju B, Cryer PE. Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon? Am J Physiol Endocrinol Metab 2005; 289: E181-6.
-
(2005)
Am J Physiol Endocrinol Metab
, vol.289
-
-
Raju, B.1
Cryer, P.E.2
-
25
-
-
0025777064
-
Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients
-
Roberge JN, Brubaker PL. Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients. Endocrinology 1991; 128: 3169-74.
-
(1991)
Endocrinology
, vol.128
, pp. 3169-3174
-
-
Roberge, J.N.1
Brubaker, P.L.2
-
26
-
-
34648836543
-
An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics
-
Jauslin PM, Silber HE, Frey N, Gieschke R, Simonsson US, Jorga K, Karlsson MO. An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics. J Clin Pharmacol 2007; 47: 1244-55.
-
(2007)
J Clin Pharmacol
, vol.47
, pp. 1244-1255
-
-
Jauslin, P.M.1
Silber, H.E.2
Frey, N.3
Gieschke, R.4
Simonsson, U.S.5
Jorga, K.6
Karlsson, M.O.7
-
27
-
-
0141669196
-
Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes
-
Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 2003; 26: 2835-41.
-
(2003)
Diabetes Care
, vol.26
, pp. 2835-2841
-
-
Meneilly, G.S.1
Greig, N.2
Tildesley, H.3
Habener, J.F.4
Egan, J.M.5
Elahi, D.6
-
28
-
-
0042668287
-
Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes
-
Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Ehlers MR, Egan JM, Elahi D. Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes. Diabetes Care 2003; 26: 837-42.
-
(2003)
Diabetes Care
, vol.26
, pp. 837-842
-
-
Meneilly, G.S.1
McIntosh, C.H.2
Pederson, R.A.3
Habener, J.F.4
Ehlers, M.R.5
Egan, J.M.6
Elahi, D.7
-
29
-
-
0034766032
-
peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes
-
Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Glucagon-like ED. peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes. J Gerontol A Biol Sci Med Sci 2001; 56: M681-5.
-
(2001)
J Gerontol A Biol Sci Med Sci
, vol.56
-
-
Meneilly, G.S.1
McIntosh, C.H.2
Pederson, R.A.3
Habener, J.F.4
Gingerich, R.5
Egan, J.M.6
Glucagon-like, E.D.7
-
30
-
-
0035514550
-
Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes
-
Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Finegood DT, Elahi D. Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care 2001; 24: 1951-6.
-
(2001)
Diabetes Care
, vol.24
, pp. 1951-1956
-
-
Meneilly, G.S.1
McIntosh, C.H.2
Pederson, R.A.3
Habener, J.F.4
Gingerich, R.5
Egan, J.M.6
Finegood, D.T.7
Elahi, D.8
-
31
-
-
0036342717
-
Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state
-
Egan JM, Meneilly GS, Habener JF, Elahi D. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 2002; 87: 3768-73.
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 3768-3773
-
-
Egan, J.M.1
Meneilly, G.S.2
Habener, J.F.3
Elahi, D.4
-
32
-
-
0030010364
-
The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones
-
Toft-Nielson M, Madsbad S, Holst JJ. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 1996; 45: 552-6.
-
(1996)
Diabetes
, vol.45
, pp. 552-556
-
-
Toft-Nielson, M.1
Madsbad, S.2
Holst, J.J.3
-
33
-
-
0029745122
-
GLP-1 does not not acutely affect insulin sensitivity in healthy man
-
Orskov L, Holst JJ, Moller J, Orskov C, Moller N, Alberti KG, Schmitz O. GLP-1 does not not acutely affect insulin sensitivity in healthy man. Diabetologia 1996; 39: 1227-32.
-
(1996)
Diabetologia
, vol.39
, pp. 1227-1232
-
-
Orskov, L.1
Holst, J.J.2
Moller, J.3
Orskov, C.4
Moller, N.5
Alberti, K.G.6
Schmitz, O.7
-
34
-
-
0030798846
-
Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans
-
Larsson H, Holst JJ, Ahren B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 1997; 160: 413-22.
-
(1997)
Acta Physiol Scand
, vol.160
, pp. 413-422
-
-
Larsson, H.1
Holst, J.J.2
Ahren, B.3
-
35
-
-
0036035521
-
Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans
-
Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA. Lack of effect of exendin-4 and glucagon-like peptide-1-(7, 36)-amide on insulin action in non-diabetic humans. Diabetologia 2002; 45: 1410-5.
-
(2002)
Diabetologia
, vol.45
, pp. 1410-1415
-
-
Vella, A.1
Shah, P.2
Reed, A.S.3
Adkins, A.S.4
Basu, R.5
Rizza, R.A.6
-
36
-
-
0031756220
-
Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia
-
Ryan AS, Egan JM, Habener JF, Elahi D. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 1998; 83: 2399-404.
-
(1998)
J Clin Endocrinol Metab
, vol.83
, pp. 2399-2404
-
-
Ryan, A.S.1
Egan, J.M.2
Habener, J.F.3
Elahi, D.4
-
37
-
-
0028296643
-
Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal
-
D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 1994; 93: 2263-6.
-
(1994)
J Clin Invest
, vol.93
, pp. 2263-2266
-
-
D'Alessio, D.A.1
Kahn, S.E.2
Leusner, C.R.3
Ensinck, J.W.4
-
38
-
-
39049141231
-
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes
-
Azuma K, Radikova Z, Mancino J, Toledo FG, Thomas E, Kangani C, Dalla Man C, Cobelli C, Holst JJ, Deacon CF, He Y, Ligueros-Saylan M, Serra D, Foley JE, Kelley DE. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 459-64.
-
(2008)
J Clin Endocrinol Metab
, vol.93
, pp. 459-464
-
-
Azuma, K.1
Radikova, Z.2
Mancino, J.3
Toledo, F.G.4
Thomas, E.5
Kangani, C.6
Dalla Man, C.7
Cobelli, C.8
Holst, J.J.9
Deacon, C.F.10
He, Y.11
Ligueros-Saylan, M.12
Serra, D.13
Foley, J.E.14
Kelley, D.E.15
-
39
-
-
77952588236
-
A model of GLP-1 action on insulin secretion in nondiabetic subjects
-
Dalla Man C, Micheletto F, Sathananthan A, Rizza RA, Vella A, Cobelli C. A model of GLP-1 action on insulin secretion in nondiabetic subjects. Am J Physiol Endocrinol Metab 2010; 298: E1115-21.
-
(2010)
Am J Physiol Endocrinol Metab
, vol.298
-
-
Dalla Man, C.1
Micheletto, F.2
Sathananthan, A.3
Rizza, R.A.4
Vella, A.5
Cobelli, C.6
-
40
-
-
77954866977
-
The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose
-
Bock G, Dalla Man C, Micheletto F, Basu R, Giesler PD, Laugen J, Deacon CF, Holst JJ, Toffolo G, Cobelli C, Rizza RA, Vella A. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol (Oxf) 2010; 73: 189-96.
-
(2010)
Clin Endocrinol (Oxf)
, vol.73
, pp. 189-196
-
-
Bock, G.1
Dalla Man, C.2
Micheletto, F.3
Basu, R.4
Giesler, P.D.5
Laugen, J.6
Deacon, C.F.7
Holst, J.J.8
Toffolo, G.9
Cobelli, C.10
Rizza, R.A.11
Vella, A.12
-
41
-
-
28844482322
-
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses
-
Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78: 675-88.
-
(2005)
Clin Pharmacol Ther
, vol.78
, pp. 675-688
-
-
Herman, G.A.1
Stevens, C.2
Van Dyck, K.3
Bergman, A.4
Yi, B.5
De Smet, M.6
Snyder, K.7
Hilliard, D.8
Tanen, M.9
Tanaka, W.10
Wang, A.Q.11
Zeng, W.12
Musson, D.13
Winchell, G.14
Davies, M.J.15
Ramael, S.16
Gottesdiener, K.M.17
Wagner, J.A.18
-
42
-
-
76949098068
-
Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations
-
Marfella R, Barbieri M, Grella R, Rizzo MR, Nicoletti GF, Paolisso G. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 2010; 24: 79-83.
-
(2010)
J Diabetes Complications
, vol.24
, pp. 79-83
-
-
Marfella, R.1
Barbieri, M.2
Grella, R.3
Rizzo, M.R.4
Nicoletti, G.F.5
Paolisso, G.6
|